Hosted on MSN1mon
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million. Bluebird makes three gene therapies: Zynteglo for beta thalassemia, Lyfgenia for sickle cell ...
Swissinfo7y
GM plants in bird feed found in non-GMO Switzerland
Switzerland and GMOs In 2005, the Swiss people voted for a five-year ban on GMOs, which was then extended by parliament in 2010 until 2013 and once again in 2012 until 2017.